Literature DB >> 25333451

Raf-interactome in tuning the complexity and diversity of Raf function.

Su An1, Yang Yang, Richard Ward, Ying Liu, Xiao-Xi Guo, Tian-Rui Xu.   

Abstract

Raf kinases have been intensely studied subsequent to their discovery 30 years ago. The Ras-Raf-mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-extracellular signal-regulated kinase/mitogen-activated protein kinase (Ras-Raf-MEK-ERK/MAPK) signaling pathway is at the heart of the signaling networks that control many fundamental cellular processes and Raf kinases takes centre stage in the MAPK pathway, which is now appreciated to be one of the most common sources of the oncogenic mutations in cancer. The dependency of tumors on this pathway has been clearly demonstrated by targeting its key nodes; however, blockade of the central components of the MAPK pathway may have some unexpected side effects. Over recent years, the Raf-interactome or Raf-interacting proteins have emerged as promising targets for protein-directed cancer therapy. This review focuses on the diversity of Raf-interacting proteins and discusses the mechanisms by which these proteins regulate Raf function, as well as the implications of targeting Raf-interacting proteins in the treatment of human cancer.
© 2014 FEBS.

Entities:  

Keywords:  Raf; Ras; cancer; interactome; mitogen-activated protein kinase

Mesh:

Substances:

Year:  2014        PMID: 25333451     DOI: 10.1111/febs.13113

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  4 in total

1.  ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism.

Authors:  David H Peng; Samrat T Kundu; Jared J Fradette; Lixia Diao; Pan Tong; Lauren A Byers; Jing Wang; Jaime Rodriguez Canales; Pamela A Villalobos; Barbara Mino; Yanan Yang; Rosalba Minelli; Michael D Peoples; Christopher A Bristow; Timothy P Heffernan; Alessandro Carugo; Ignacio I Wistuba; Don L Gibbons
Journal:  Sci Transl Med       Date:  2019-03-13       Impact factor: 17.956

Review 2.  Accessory proteins of the RAS-MAPK pathway: moving from the side line to the front line.

Authors:  Silke Pudewell; Christoph Wittich; Neda S Kazemein Jasemi; Farhad Bazgir; Mohammad R Ahmadian
Journal:  Commun Biol       Date:  2021-06-08

3.  An eIF3a gene mutation dysregulates myocardium growth with left ventricular noncompaction via the p-ERK1/2 pathway.

Authors:  Mei Ge; Xuehan Bai; Aoyi Liu; Lingjuan Liu; Jie Tian; Tiewei Lu
Journal:  Genes Dis       Date:  2020-02-29

Review 4.  Eukaryotic translation initiation factors as promising targets in cancer therapy.

Authors:  Peiqi Hao; Jiaojiao Yu; Richard Ward; Yin Liu; Qiao Hao; Su An; Tianrui Xu
Journal:  Cell Commun Signal       Date:  2020-11-04       Impact factor: 5.712

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.